CARs that target other B-cell lineage antigens such as CD20 and CD22 have been incorporated in the hope of combatting both tumor heterogeneity as well as antigen escape with dual targeting CARs such as the anti-CD19/CD22 CAR [21,27]. The gene discussed is CD22; the disease is neoplasm.